Phase II Study of Doxorubicin and Avastin® in Sarcoma.

Stopped early · Phase 2

Conditions studied: Sarcoma, Soft Tissue Sarcoma

In brief

This research is being done to find out if adding a drug called Avastin to an already approved regimen used for soft-tissue sarcoma, Doxorubicin, will improve overall survival, and slow disease progression. The study will also evaluate the overall safety of combining these drugs. It is not known if combining these drugs will improve outcome. Avastin has been approved for the treatment of metastatic carcinoma of the colon or rectum. It is not approved for the treatment of soft-tissue sarcoma when added to Doxorubicin.

Key facts

Study ID: NCT00755261
Run by: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
People needed: 4
Starts: 2008-09-01
Expected to finish: 2010-11-01
Last updated by the study team: 2015-05-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Pathologically confirmed intermediate or high grade locally advanced or metastatic soft tissue sarcoma.
The presence of measurable disease
Normal renal function (spot dipstick <2** or urine protein: creatinine ratio >1.0
Normal Hepatic function (total bilirubin within JOHC normal limits, transaminases (AST and ALT <3 times upper limit of normal
Hematologic parameters as defined as ANC >1500/mm³ and Platelets > 100,000/mm³.
Performance status 0-1 on ECOG scale
Use of effective means of contraception (men and women) in subjects of child-bearing age
No prior use of mesna, adriamycin, ifosfamide or Avastin®.
Baseline ECHO or MUGA with LVEF > or = 50-60%.
Age ≥ 18

You may not qualify if…

Major surgery within 28 days
History of proteinuria > 1+
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored Avastin® cancer study
Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications)
Any prior history of hypertensive crisis or hypertensive encephalopathy
New York Heart Association (NYHA) Grade II or greater congestive heart failure (see Appendix E)
History of myocardial infarction or unstable angina within 6 months prior to study enrollment
History of stroke or transient ischemic attack within 6 months prior to study enrollment
Symptomatic peripheral vascular disease
Significant vascular disease (e.g., aortic aneurysm, aortic dissection)
Evidence of bleeding diathesis or coagulopathy
Current or recent (within 10 days of enrollment) use of aspirin (>325 mg/day) or chronic use of other NSAIDs
Current, ongoing treatment with full-dose warfarin or its equivalent (i.e., unfractionated and/or low molecular weight heparin).
Known central nervous system or brain metastases
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, anticipation of need for major surgical procedure during the course of the study
Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment
Pregnant (positive pregnancy test) or lactating
Proteinuria :creatinine (UPC) ratio ≥ 1.0 at screening or Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible).
History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
Serious, non-healing wound, ulcer, or bone fracture
Known hypersensitivity to any component of Avastin®
Inability to comply with study and/or follow-up procedures

Where it is running

Johns Hopkins SKCCC — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.